Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| ciliated cell | 15 studies | 29% ± 10% | |
| natural killer cell | 8 studies | 21% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 22% ± 5% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 23% ± 1% |
Insufficient scRNA-seq data for expression of SLFN13 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 100% | 1798.14 | 653 / 653 | 99% | 11.83 | 597 / 605 |
| kidney | 90% | 679.72 | 80 / 89 | 92% | 15.83 | 827 / 901 |
| lung | 100% | 1621.96 | 577 / 578 | 80% | 11.84 | 928 / 1155 |
| esophagus | 98% | 870.82 | 1419 / 1445 | 77% | 11.20 | 141 / 183 |
| uterus | 96% | 771.35 | 163 / 170 | 77% | 23.29 | 352 / 459 |
| ovary | 63% | 247.98 | 114 / 180 | 96% | 12.55 | 412 / 430 |
| breast | 99% | 1200.44 | 456 / 459 | 56% | 5.84 | 621 / 1118 |
| pancreas | 65% | 240.35 | 213 / 328 | 89% | 8.90 | 158 / 178 |
| stomach | 97% | 1148.16 | 350 / 359 | 51% | 5.49 | 145 / 286 |
| bladder | 90% | 481.24 | 19 / 21 | 56% | 7.74 | 282 / 504 |
| intestine | 100% | 1695.61 | 965 / 966 | 44% | 4.27 | 232 / 527 |
| skin | 79% | 381.89 | 1423 / 1809 | 29% | 1.79 | 138 / 472 |
| prostate | 97% | 713.21 | 238 / 245 | 9% | 0.44 | 45 / 502 |
| spleen | 100% | 3839.16 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 99% | 831.44 | 1189 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 2792.38 | 910 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 8.69 | 27 / 29 |
| liver | 63% | 233.11 | 143 / 226 | 25% | 5.02 | 102 / 406 |
| adrenal gland | 64% | 214.48 | 164 / 258 | 19% | 1.39 | 43 / 230 |
| tonsil | 0% | 0 | 0 / 0 | 80% | 20.08 | 36 / 45 |
| blood vessel | 64% | 485.59 | 853 / 1335 | 0% | 0 | 0 / 0 |
| heart | 62% | 242.35 | 534 / 861 | 0% | 0 | 0 / 0 |
| brain | 14% | 44.27 | 371 / 2642 | 9% | 0.82 | 65 / 705 |
| eye | 0% | 0 | 0 / 0 | 11% | 0.55 | 9 / 80 |
| muscle | 2% | 5.64 | 19 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0016078 | Biological process | tRNA decay |
| GO_0051607 | Biological process | defense response to virus |
| GO_0016075 | Biological process | rRNA catabolic process |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000049 | Molecular function | tRNA binding |
| GO_0004521 | Molecular function | RNA endonuclease activity |
| GO_0008270 | Molecular function | zinc ion binding |
| GO_0005524 | Molecular function | ATP binding |
| Gene name | SLFN13 |
| Protein name | Schlafen family member 13 Schlafen family member 13 (EC 3.1.-.-) (Schlafen-13) (hSLFN13) SLFN13 protein |
| Synonyms | |
| Description | FUNCTION: Endoribonuclease that cleaves tRNAs and rRNAs . Cleaves tRNAs 11 nucleotides from the 3'-terminus at the acceptor stem . Does not act on tRNA(Sec) . Able to restrict HIV-1 virus replication; ability to inhibit HIV-1 replication is dependent on endoribonuclease activity . . |
| Accessions | Q68D06 ENST00000533791.5 [Q68D06-1] ENST00000542635.5 [Q68D06-1] B7ZVY5 ENST00000534689.5 [Q68D06-2] ENST00000532210.5 E9PMV5 ENST00000524511.5 ENST00000530782.5 ENST00000526861.5 [Q68D06-1] ENST00000531588.1 E9PKT7 ENST00000285013.11 [Q68D06-1] K7EPV8 E9PM29 |
